Sarepta Therapeutics (SRPT) volatility pulls back on sharp rally on FDA approval

Sarepta Therapeutics (NASDAQ: SRPT) is recently up $2.05 to $50.99 in the premarket after saying it sees the U.S. annual cost of eteplirsen at $300,000, a day after rallying 73% on the FDA approval of eteplirsen. September weekly call option implied volatility is at 145, October is at 88; compared to its 52-week range of 79 to 399.

You May Also Be Interested In

• Apple announces A20 Pro chip based on 2nm technology
• Mizuho Defends Sarepta Therapeutics (SRPT)
• SK Hynix (SKHY) call put ratio 1.2 calls to 1 put as share price up 4.7%